Keywords: rivers, finalizes, acquisition, infergen, valeant, pharmaceuticals, finalized
Three Rivers finalizes acquisition of Infergen from Valeant
Article | 21 January 2008
Three Rivers Pharmaceuticals has finalized its acquisition of the hepatitis C drug Infergen (interferon-alpha) from fellow USA-based Valeant Pharmaceuticals, which ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
